Sangamo Therapeutics (NASDAQ: SGMO) is one of 282 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare Sangamo Therapeutics to similar businesses based on the strength of its risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of current ratings and target prices for Sangamo Therapeutics and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sangamo Therapeutics 0 1 5 0 2.83
Sangamo Therapeutics Competitors 808 3168 11489 230 2.71

Sangamo Therapeutics currently has a consensus price target of $18.60, indicating a potential upside of 22.37%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.04%. Given Sangamo Therapeutics’ rivals higher possible upside, analysts clearly believe Sangamo Therapeutics has less favorable growth aspects than its rivals.

Earnings & Valuation

This table compares Sangamo Therapeutics and its rivals gross revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Sangamo Therapeutics $19.39 million -$71.65 million -22.03
Sangamo Therapeutics Competitors $286.20 million $34.74 million 146.61

Sangamo Therapeutics’ rivals have higher revenue and earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.


This table compares Sangamo Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sangamo Therapeutics -157.66% -31.81% -23.84%
Sangamo Therapeutics Competitors -5,339.09% -435.51% -40.49%

Volatility & Risk

Sangamo Therapeutics has a beta of 3.06, meaning that its share price is 206% more volatile than the S&P 500. Comparatively, Sangamo Therapeutics’ rivals have a beta of 6.30, meaning that their average share price is 530% more volatile than the S&P 500.

Institutional and Insider Ownership

63.3% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 49.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 5.5% of Sangamo Therapeutics shares are held by insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company’s product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.

Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with's FREE daily email newsletter.